Previous close | 310.29 |
Open | 314.35 |
Bid | 240.00 x 1000 |
Ask | 318.82 x 1100 |
Day's range | 310.52 - 322.11 |
52-week range | 231.90 - 367.21 |
Volume | |
Avg. volume | 487,554 |
Market cap | 18.861B |
Beta (5Y monthly) | 0.95 |
PE ratio (TTM) | 31.23 |
EPS (TTM) | 10.18 |
Earnings date | 07 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 26 Nov 1996 |
1y target est | 320.78 |
Waters' (WAT) second-quarter 2024 results are likely to reflect strength in the large molecule and PFAS testing markets amid weakening demand in China.
Waters Corporation (NYSE: WAT) announced today the global release of the TA Instruments™ Rapid Screening-Differential Scanning Calorimeter (TA Instruments RS-DSC), designed for biopharmaceutical developers. The TA Instruments RS-DSC is a high-throughput DSC for precise thermal stability testing of high-concentration biologic formulations specifically for antibody drugs and engineered proteins.
Waters Corporation (NYSE:WAT) will hold its Q2 2024 financial results conference call live on Wednesday, July 31st, 2024 at 8:00 a.m. Eastern Time. A live webcast of the presentation will be available on Waters Investor Relations website at https://ir.waters.com. A replay of the webcast will also be available until at least August 28th, 2024, at midnight Eastern Time.